🇺🇸 FDA
Patent

US 7846907

Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene

granted A61KA61K38/00A61P

Quick answer

US patent 7846907 (Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61P, A61P35/00